

**Economic and Social Council**

Distr.: General
26 February 2016

Original: English

2016 session

24 July 2015-27 July 2016

Agenda item 4

Elections, nominations, confirmations and appointments

Election of two members of the International Narcotics Control Board from among candidates nominated by the World Health Organization**Note by the Secretary-General**

1. The present note contains information on candidates nominated by the World Health Organization (WHO) for election to the International Narcotics Control Board. Information on candidates nominated by Governments is contained in documents [E/2016/9/Add.11](#) and Add.12.

2. In accordance with established procedure, the Secretary-General invited the Director General of WHO to submit a list of candidates for election to membership in the International Narcotics Control Board for the period from 2 March 2017 to 1 March 2022 on the expiration of the terms of office of two members of the Board nominated by WHO and elected by the Economic and Social Council in 2011. The posts are currently occupied by Richard Mattick (Australia) and Sri Suryawati (Indonesia).

3. As at 24 February 2016, five candidates had been proposed by WHO. Their names are given below in alphabetical order:

Mohammed Tamouh **Abou-Saleh**
Cornelis **de Joncheere**
Richard **Mattick** (*re-election*)
Lukas **Radbruch**
Emran **Razaghi**

Syrian Arab Republic
Netherlands
Australia
Germany
Iran (Islamic Republic of)

4. The biographical information that was transmitted with the proposals for candidatures is contained in the annex to the present note.



5. In accordance with article 9, paragraph 2, of the Single Convention on Narcotic Drugs, 1961,¹ as amended by the 1972 Protocol thereto,² members of the Board shall not hold positions or engage in any activity that would be liable to impair their impartiality in the exercise of their functions. Positions and activities of the following are, in particular, incompatible with membership of the Board: persons who hold government posts, are in the paid service of their Governments or are acting under instructions from their Governments; persons who represent a Government at national or international forums on drug-related issues; and persons who are engaged in any activity, whether private or public, that might be liable to impair their impartiality in the exercise of their functions on the Board or whose activity is in conflict with the functions of the Board.

6. Document [E/2016/9/Add.11](#) contains information on the number, length and place of meetings of the Board in 2013, on payments to members and on present membership (annex I); articles 9 (Composition and functions of the Board) and 10 (Terms of office and remuneration of members of the Board) of the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol thereto (annex II); information on qualifications and other conditions regarding membership of the Board (annex III); and a list of the States parties to the Single Convention of 1961 and that Convention as amended by the 1972 Protocol thereto, the Convention on Psychotropic Substances, 1971,³ and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988⁴ (annex IV).

¹ United Nations, *Treaty Series*, vol. 520, No. 7515.

² *Ibid.*, vol. 976, No. 14151.

³ *Ibid.*, vol. 1019, No. 14956.

⁴ United Nations publication, Sales No. E.91.XI.6.

Annex

Biographical information on candidates for election to the International Narcotics Control Board*

1. Mohammed Tamouh Abou-Saleh (Syrian Arab Republic)

Education

Doctor of Philosophy (Ph.D.), University of Surrey, United Kingdom 1985; Fellow of the Royal College of Psychiatrists (F.R.C.Psych), United Kingdom, 1996; Member of the Royal College of Psychiatrists (M.R.C.Psych), United Kingdom, 1980; Master of Philosophy (M.Phil.), Edinburgh, United Kingdom, 1980; Bachelor of Medicine (M.B.) and Bachelor of Surgery (Ch.B.), Baghdad, 1975.

Present posts

Professor of Psychiatry, Division of Mental Health, St George's, University of London, United Kingdom; Honorary Consultant in Addiction Psychiatry, South West London and St George's Mental Health Trust; Consultant Psychiatrist, Psychiatric and Psychological Consulting Services, London; Consultant Psychiatrist, Helen Bamber Foundation, London; Medical Examiner and Supervisor, General Medical Council; Vice-President of the World Federation for Mental Health for Constituency Building and the Eastern Mediterranean Region; Chairman of the World Psychiatric Association Section on Biological Psychiatry.

Previous posts

Consultant for the Ministry of Health of the United Arab Emirates for the development of the National Mental Health Strategy and Implementation Plan and Short, Medium and Long-term National Strategies for Addictions and Implementation Plans (17-21 January 2016); Chairman of the WHO Regional Office for the Eastern Mediterranean (EMRO) Final Consultation on the Development of a Substance Use Information System (2013); Consultant for the Regional Office for the Eastern Mediterranean on the development of the National Addictions Strategy and Implementation Plan in Egypt (2013); Chairman of the Supreme Council of Health Workstream for Addictions under the National Mental Health Strategy to develop the National Action Plan for Addictions in Qatar (2012-2013); Chairman of the Minister of Health Commission for the Reform of Legislation Related to Criminalization of Drug Use in Qatar (2012-2013); Chief Executive Officer, Naufar, Qatar Addiction Treatment and Rehabilitation Centre Project (2011-2013).

Clinical Responsibilities

Previous (South West London and St George's Mental Health Trust); Consultant, the National Inpatient Addiction Treatment and Research Unit, Springfield University Hospital, United Kingdom (April 1998-2011); Consultant for the Sutton Community Drug Team, United Kingdom (August 2005-2011); Honorary Consultant of the Drug and Alcohol Liaison Team, St George's Hospital (October 2003-Jul 2005); Honorary Consultant for the Drug Dependency Unit, St George's Hospital (October 2003-July

* Curricula vitae are issued without formal editing.

2005); Honorary Consultant for the Addiction Resource Agency for Commissioners, United Kingdom (October 2003-May 2004); Honorary Consultant for the Sutton and Merton Community Drug Team (May 2001-September 2003); Honorary Consultant for the Primary Care Liaison Team (1999-2003); Honorary Consultant for the Addiction Treatment Centre, Queen Mary's University Hospital (April 1998-April 2001); Honorary Consultant in Liaison Psychiatry at the Royal Liverpool Hospital, United Kingdom (1989-1991); Honorary Consultant Psychiatrist (Community Psychiatry) at Sefton General Hospital, Liverpool, United Kingdom, (1986-1989); Honorary Consultant Psychiatrist with inpatient duties at Al Ain Hospital and outpatient clinics at Tawam and Al Ain University Hospitals, Al Ain Medical District, United Arab Emirates (1991-1998).

Previous appointments

Lead, Addictions Research Group, Division of Mental Health, St George's, University of London (October 2007-April 2010); Director of Research and Development, South West London and St George's Mental Health NHS Trust (October 2002-2008); Research Co-coordinator, Division of Mental Health, St George's, University of London (October 2002-2006); Clinical Director, South West London and St George's Mental Health NHS Trust (April 1998-January 2004); Honorary Consultant Psychiatrist, South West London and St George's Mental Health NHS Trust (April 1998-April 2010); Reader in Addictive Behaviour, Division of Mental Health, St George's, University of London (April 1998-September 2005); Senior Research Fellow, University of Liverpool, United Kingdom (1996-1998); Reader in Psychiatry, University of Liverpool (October 1992-September 1994); Associate Dean for Clinical Affairs, United Arab Emirates University (December 1993-August 1996); Professor and Chairman of the Department of Psychiatry and Behavioural Sciences, United Arab Emirates University (distinguished Professor contract) (December 1991-March 1998); Acting Head of the University Department of Psychiatry, University of Liverpool (October 1989-September 1990); Senior Lecturer in Psychiatry, University of Liverpool; and Honorary Consultant Psychiatrist at the Royal Liverpool Hospital (1986-1991); Senior Registrar in Psychiatry, St. George's Hospital, London (1982-1985); Senior Registrar in Psychopharmacology, MRC Neuropsychiatry Laboratory, West Park Hospital, Epsom, Surrey, United Kingdom (1980-1982).

Selected publications

Over 250 publications, including 135 publications in refereed journals, 25 letters to academic journals, 22 publications related to teaching, 19 papers in professional journals, 45 chapters in books, 2 manuals and 14 other publications, excluding abstracts.

Co-editor of *Principles and Practice of Geriatric Psychiatry* (Editors: Copeland, J.R.M., Abou-Saleh, M.T. and Blazer, D., first edition (1994); second edition (2002); and editor, (Editors: Abou-Saleh, M.T., Katona, C. and Kumar, A.), third edition (2010); (Editors: Abou-Saleh, M.T. and Foley, S.) (2008); "The Epidemiology of Hepatitis C in Drug Users", in *Addictive Disorders and their Treatment* (in press); Bener, A., Ghuloum, S., Abou-Saleh M.T., "Prevalence, symptom patterns and comorbidity of anxiety and depressive disorders in primary care in Qatar", *Soc Psychiatry Psychiatr Epidemiol.* 2012 47(3): 439-46; Abou-Saleh, M.T., Rice, P. and Foley, S. (2012), Hepatitis C Testing in Drug Users

Using the Dried Blood Spot Test and the Uptake of an Innovative Self-administered DBS Test, in *Addictive Disorders and Their Treatment*; Whicher, E. V., Utku, F., Schirmer, G., Davis, P., Abou-Saleh, M.T., (2012), “Pilot Project to Evaluate the Effectiveness and Acceptability of Single-session Brief Counseling for the Prevention of Substance Misuse in Pregnant Adolescents”, in *Addictive Disorders and Their Treatment*: vol. 11, No. 1, pp. 43-49; Abou-Saleh, M. T. and Abdelalaim, M. “Mental Health Law in Qatar”, in *International Psychiatry*, vol. 10 (2013), pp. 88-90; Abou-Saleh, M.T. and Mobayed, M., “Mental Health in Post-conflict Syria”, in *International Psychiatry*, vol. 10 (2013), pp. 58-60; Passetti, F.; Verdejo-Garcia, A.; Abou-Saleh, M.T. “Comparatively preserved impulse control in late-onset opiate users”, in *Psychopharmacology* (Berl); vol. 230, No. 3 (2013), pp. 499-505; Sharma, V. and Abou-Saleh, M.T. and others, “The Global Mental Health Assessment Tool: validation of the Arabic version in *Eastern Mediterranean Health Journal* vol. 19, No. 11, pp. 905-908; Kronfol, Z. and Abou-Saleh, M.T., “The State of Psychiatry in the Arab Middle East, in *Psychiatric Times* (2015); Bener, A., Abou-Saleh, M.T., Dafecah, E.E., Bhugra, D. (2015); “The prevalence and burden of psychiatric disorders in primary health care visits in Qatar: too little time?”, in *Journal of Family Medicine and Primary Care*, vol. 4, No. 1: pp. 89-95; Millar, H., Abou-Saleh, M.T. “Multimorbidity in Mentally ill People: The Need for a Person-centered Integrated Approach,” in *International, Journal of Person-Centred Medicine* No. 5 (2015), pp. 28-33; Abou-Saleh, M.T., Hughes, P.; “Mental Health of Syrian Refugees: Looking Backwards and Forwards”, in *Lancet Psychiatry* vol 2, No. 10 (2015), pp. 870-871.

Awards

“B” Merit Award (renewed for 5 years), October 2004.

2. Cornelis de Joncheere (The Netherlands)

Education

Doctor of Pharmacy (Pharm.D) and Master of Science (M.Sc.) in Pharmacy, University of Groningen and University of Amsterdam, The Netherlands; Master’s in Business Administration, University of San Diego, United States of America/ San José, Costa Rica; Master of Business Administration (MBA), National University, San Diego, California, United States/San José, Costa Rica (1992-1993); Doctor of Pharmacy (Pharm.D) (Apothekersexamen, professional pharmacist’s licence), University of Amsterdam, the Netherlands (1980-1981); Bachelor of Science (B.Sc.) and Master of Science (M.Sc.) Pharmacy, cum Laude (Honorary student), State University Groningen, the Netherlands (1972-1979).

Present post

Director, Department of Essential Medicines and Health Products at the World Health Organization (WHO) in Geneva (since 1998) (retiring from WHO in 2016).

Previous posts

WHO Representative, Kiev, Ukraine, (2011-2012); WHO Regional Adviser for Pharmaceuticals and Health Technologies, WHO Regional Office for Europe, Copenhagen, Denmark (1996-2010); National Essential Drugs Programme

Coordinator, Pan American Health Organization/World Health Organization (PAHO/WHO), Brazil (1994-1996); Pharmacist, Essential Drugs Projects Coordinator (PAHO/WHO), Costa Rica (1988-1993); Pharmaceutical expert (PAHO/WHO), Panama (1986-1988); Pharmaceutical supply expert in Yemen, Ministry of Foreign Affairs, Directorate for International Cooperation, the Netherlands (1982-1985); Hospital and Community Pharmacy in Amsterdam, the Netherlands (1981-1982).

Selected memberships

President of the WHO/Europe Staff Association (2006-2010); Member of the WHO Guidelines Review Committee (2007-2011); Member of the National Institute for Health and Clinical Excellence International Advisory group, United Kingdom (since 2009); Member of the Royal Dutch Pharmaceutical Society and the International Pharmaceutical Federation; Council of Europe European Directorate for the Quality of Medicines Pharmaceutical Experts Committee; Drug Information Association; European Society of Clinical Pharmacy; United States Pharmacopeia; International Society of Drug Bulletins; European Drug Utilization Research Group; International Society for Pharmacoepidemiology; International Society for Pharmacoeconomics and Outcomes Research; European Generic Medicines Association.

Selected publications

Leopold, C., Mantei-Teeuwisse, A.K., Vogler, S., Valkova, S., de Joncheere, K., Leufkens, H.G.M., Wagner, A., Ross-Degnan, D., Laing, R., "Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries", in *Bulletin of the World Health Organization* (2014); Leopold, C., Mantei-Teeuwisse, A.K., Vogler, S., de Joncheere, K., Laing, R.O., Leufkens H.G.M., "Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries", in *Health Policy*, vol. 112 (2013), pp. 209-16; Leopold, C., Vogler, S., Mantei-Teeuwisse, A., de Joncheere, K., Leufkens, H.G.M., Laing, R., "Differences in external price referencing in Europe — a descriptive overview", in: *Health Policy* vol. 104 (2012). p. 1; Leopold, C., Mantei-Teeuwisse, A.K., Seyfang, L., Vogler, S., de Joncheere, K., Laing, R.O., Leufkens, H.G.M., "Impact of External Price Referencing on Medicine Prices — A Price Comparison Among 14 European Countries", in *Southern Med Review*, vol. 5, No. 2 (2012), pp. 34-41; Vogler, S., Zimmermann, N., Leopold, C., de Joncheere, K., "Pharmaceutical policies in European countries in response to the global financial crisis", In: *Southern Med Review*, Vol. 4 (2011), pp. 22-32; "Differences in External Price Referencing in Europe — a descriptive overview", Leopold, C., Vogler, S., Mantei-Teeuwisse, A.K., de Joncheere, C.P., Leufkens, H.G.M., Laing, R. (2011), submitted to "Health policy and Planning Health information for patients and the general public", produced by the German Institute for Quality and Efficiency in Health Care: a review by the World Health Organization (2008/2009); Kees de Joncheere, Gerald Gartlehner, Laragh Gallogly, Pertti Mustajoki, Govin Permanand. WHO, Regional Office for Europe (May 2010); "Evaluation of the access to HIV/AIDS treatment and care in Lithuania"; Irina Eramova, Kees de Joncheere, Ulrich Laukamm-Josten, Luis Mendao, Signe Rotberga, Maria Skarphedinsdottir and Roger Drew (WHO Regional Office for Europe, April 2010); "Review of the pharmaceutical sector with a view to

developing a national medicines policy in Estonia” (WHO/EURO, May 2009); “Evaluation of the access to HIV/AIDS treatment and care in Latvia”; Kees de Joncheere, Irina Eramova, Jenni Kehler, Ulrich Laukamm-Josten, Signe Rotberga, Anna Zakowicz and Roger Drew (May 2009); WHO/EURO Control of medicines promotion in Central European countries (WHO/EURO, November 2008); “The Clinical Guideline programme of the National Institute for Health and Clinical Excellence” (May 2006), a review by WHO; WHO # 5063284 (May 2006); “Technology Appraisal programme of the National Institute of Clinical Excellence”, a review by WHO, WHO #5045738 (July 2003); Walley, T., Mossialos E.A., de Joncheere C.P., “Supply and regulation of medicines” (2005); *British Medical Journal*, vol. 331, pp. 171-172; “Alternatives to the fourth hurdle: Clinical and cost-effectiveness analyses in Europe”; Kees de Joncheere, ISPOR Connections (15 August, 2005). Vol, no 4; “The pharmaceutical sector and regulation in the countries of central and eastern Europe”; Monique Mrazek, Kees de Joncheere, Guenka Petrova, Elias Mossialos; pp. 323-334 in *Regulating Pharmaceuticals in Europe*, ed. Elias Mossialos, Monique Mrazek, Tom Walley (Open University Press, Berkshire, United Kingdom, 2004), ISBN 0 335 21465.

Selected meetings attended

Member of the Organizing Committee of the European Conference on Medicines Pricing and Reimbursement, Vienna, (2011-2015); Member of the Organizing Committee of the International Conference on Improving Use of Medicines, 2012; Meetings for the Inter-Governmental Working Group on Public Health, Innovation and Intellectual Property, as established by WHA 59.24, and WHO/PHI from 2006 to 2011; Meeting of the Intergovernmental working group on SSFFC medicines 2011; International Conference on Harmonization; London School of Economics Executive courses on pharmaceutical pricing and reimbursement in Europe; European Union meetings (Pharmaceutical Forum and G10 Meetings, Italian, Dutch (2004), Portuguese (2007) and Czech (2009); European Union presidency meeting, Portuguese presidency in April 2000 on Medicines and Public Health, plus the Bangemann round table conferences on the single market in pharmaceuticals); WHO Geneva meetings, including the IPC group (coordination with pharmaceutical experts from the United Nations Children’s Fund, World Bank, Global Fund and other international organizations).

3. Richard Phillip Mattick (Australia)

Education

Bachelor of Science (Psychology), Honours, Class 1, University of New South Wales (UNSW), 1982; Master of Psychology (Clinical), UNSW, 1989; Doctor of Philosophy, UNSW, 1988; Certificate in Neuroanatomy, Anatomy, UNSW, 1992.

Present posts

Professor, National Drug and Alcohol Research Centre (NDARC), and Professor, Brain Sciences, UNSW; Australian Government National Health and Medical Research Council Principal Research Fellow (2013-2017); Member, International Narcotics Control Board (INCB), United Nations Office in Vienna, and Member, INCB Standing Estimates Committee, 2015-2017).

Previous posts

Executive Director and Professor, NDARC, Faculty of Medicine, UNSW (2002-2009); Acting Executive Director, Associate Professor and Director of Research, NDARC, UNSW (1996-2002); Director of Research and Associate Professor, NDARC, UNSW (1995); Senior Lecturer, NDARC, UNSW (1993); Honorary Consultant in Clinical Psychology, St. Vincent's Hospital, Sydney (1991-1993); Lecturer, NDARC, Faculty of Medicine, UNSW (1988-1993); Hospital Psychologist, Clinical Research Unit for Anxiety Disorders, St. Vincent's Hospital (1987 and 1988).

Selected memberships

Member, Faculty of Medicine, UNSW, 1988-current; Registered Psychologist, Psychologists Registration Board, New South Wales (NSW) (PS0021090), 1992-current; Member, Australian Psychological Society Ltd (100899), 1996-current; Member, Scientific Advisory Committee, Mental Health and Addiction Research Centre, University of Otago, New Zealand, 2002-current; Member, New South Wales Expert Advisory Group on Drugs and Alcohol, advising the NSW Minister of Health, 2004-2007; invited for reappointment from 2008-current; Member, Australian National Council on Drugs (ANCD), 2004-2007, advising the Prime Minister; invited for reappointment from 2008-2010; Member, ANCD National Illicit Drug Campaign Reference Group, 2004-2010; Member, ANCD Project Reference Group, 2004-2010; Member, Sax Institute Research Partnerships for Better Health, 2006-current; Member, Alcohol Beverages Advertising Code Adjudication Panel, appointed at the request of the Australian Government Department of Health and Ageing, 2007-current; Member, Australian Research Alliance on Children and Youth (Member number 6733); Member, NHMRC 2014 Project Grants Grant Review Panel Committee, 1 March 2014-31 December 2014.

Selected publications

"A summary of recommendations for the management of opioid dependence: The quality assurance in the treatment of drug dependence project" in *Drug and Alcohol Review*, vol. 13, No. 3, pp. 319-326; Degenhardt, L., Larney, S., Gisev, N., Trevena, J., Burns, L., Kimber, J., Shanahan, M., Butler, T., Mattick, R.P. and Weatherburn, D. (2014). "Imprisonment of opioid-dependent people in New South Wales, Australia, 2000-2012: A retrospective linkage study", *Australian New Zealand Journal of Public Health*, vol. 38, No. 2, pp. 165-170; Degenhardt, L., Larney, S., Kimber, J., Gisev, N., Farrell, M., Dobbins, T., Weatherburn, D.J., Gibson, A., Mattick, R.P., Butler, T. and Burns, L. (2014). "The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study", *Addiction*, 109, 1306-1317; Mattick, R.P., Kimber, J., Breen, C. and Davoli, M. (2014). "Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence", *Cochrane Database of Systematic Reviews* 2014, Issue 2, 84 pages; Larney, S., Gowing, L., Mattick, R.P., Farrell, M., Hall, W. and Degenhardt, L. (2014). "A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence", *Drug and Alcohol Review*, 33(2), 115-128; Larance, B., Lintzeris, N., Ali, R., Dietze, P., Jenkinson, R., White, N., Mattick, R.P. and Degenhardt, L. (2014). "The diversion and injection of a buprenorphine-naloxone soluble film formulation", *Drug and Alcohol Dependence*,

136(1), 21-27; Campbell, G., Mattick, R., Bruno, R., Larance, B., Nielsen, S., Cohen, M., Lintzeris, N., Shand, F., Hall, W., Hoban, B., Kehler, C., Farrell, M. and Degenhardt, L. (in press — accepted 8 March 2014). “Cohort protocol: The Pain and Opioids IN Treatment (POINT) study”, BMC Pharmacology and Toxicology; Clare, P., Bradford, D., Courtney, R., Martire, K. and Mattick, R.P. (in press — accepted 20 March 2014). “The relationship between socioeconomic status and ‘hardcore’ smoking over time-greater accumulation of hardened smokers in low-SES than high-SES smokers”, Tobacco Control; Clare, P., Slade, T., Courtney, R., Martire, K. and Mattick, R.P. (in press — accepted 18 June 2014). “The use of smoking cessation and quit support services by socioeconomic status over 10 years of the National Drug Strategy Household Survey. Nicotine and Tobacco Research”; Courtney, R.J., Bradford D., Martire, K., Bonevski, B., Borland, R., Doran, C., Hall, W., Farrell, M., Siahpush, M., Sanson-Fisher, R., West, R. and Mattick, R.P. (in press — accepted 16 June 2014). “A randomized clinical trial of a financial education intervention with nicotine replacement therapy (NRT) for low-socioeconomic status Australian smokers: A study protocol”, Addiction; Larance, B., Carragher, N., Mattick, R.P., Degenhardt, L., Lintzeris, N. and Ali, R. (2014 — accepted 22 May 2014).

Selected awards and grants

National Drug Strategy, Department of Human Services and Health Grant: Third national census of clients of drug or alcohol treatment service agencies, to Mattick, R.P. (\$69,144); NDARC-funded project entitled Cost-benefit analysis of methadone maintenance treatment, coordinated by Mattick, R.P. and Hall, W. (\$50,000); Drug and Alcohol Directorate, NSW Department of Health grant: Methadone maintenance treatment review, to Mattick, R.P. and Hall, W. (\$67,375); Research for Drug Abuse Advisory Committee, Commonwealth Department of Human Services and Health grant: Randomized controlled trial of an adolescent treatment programme. Mattick, R.P., Spooner, C. and Noffs, W. (\$179,874); Research grant from Drug Abuse Advisory Committee, Department of Human Services and Health, An evaluation of the NSW prison methadone program. Wodak, A., Dolan, K., and Mattick, R.P. (\$211,806); Drug and Alcohol Directorate, NSW Department of Health, Commonwealth Department of Human Services and Health and Reckitt and Colman Pharmaceuticals Pty Ltd, project: A controlled trial of buprenorphine and methadone maintenance therapy. Mattick, R.P. and Oliphant, D. (\$178,000); Research for Drug Abuse Advisory Committee, Department of Human Services and Health, “Urinary amphetamine isomer monitoring of controlled prescribing of amphetamines: A randomized controlled trial”, Wodak, A., Mattick, R.P. and Van Beek, I. (\$69,426); Commonwealth Department of Health and Human Services grant: Naltrexone and rapid detoxification. Mattick, R.P. (\$12,686); NSW Department of Health grant: Successful withdrawal from opioid replacement therapy. Mattick, R.P. (\$159,427).

Selected meetings attended

Member, WHO/UNODC Technical Guidelines on Opioid Pharmacotherapies, Guidelines Development Group 2004-2008; Member, Australian Delegation to the United Nations, Commission on Narcotic Drugs, Vienna, Austria, 13-14 March, 2007; Member, Australian Delegation to the United Nations, Commission on Narcotic Drugs, Vienna, Austria, 6th-14th March, 2008.

4. Lukas Radbruch (Germany)

Education

University Hospital Bonn, Department of Palliative Medicine.

Present post

Chair of Palliative Medicine at University of Bonn, Director of Department of Palliative Medicine of University Hospital Bonn, Director of Centre of Palliative Care of Malteser Hospital Seliger Gerhard Bonn/Rhein-Sieg (since 2010).

Previous posts

Chair of Palliative Medicine at the University of Aachen, Director of Department of Palliative Medicine of University Hospital Aachen (2003-2010); Venia legendi for Anaesthesiology and Palliative Medicine, University of Cologne (20 October 2000); Head of Pain Clinic of the Department of Anaesthesiology of the University Hospital Cologne (1994-2003); Speciality certificate Anaesthesiology (25 March 1992); Research Fellow at the Department of Anaesthesiology of the University Hospital Cologne (1987-2003); Department of Internal Medicine, St. Elisabeth-Krankenhauses Gerolstein (1985-1986); Approbation in Medicine and Dissertation (Dr.med.) in Medicine in Bonn (26 November 1985); studies of Medicine in Bonn (Germany) (1979-1985).

Selected memberships

European Association for Palliative Care (Member of the Board of Directors from 2003 to 2011, president from 2007 to 2011); Research Steering Committee of the European Association for Palliative Care (Member since 1996); International Association for Hospice and Palliative Care (Member of the Board of Directors since 2011, Incoming Chair from 2012 to 2013, Chair since 2014); International Association for the Study of Pain; Deutsche Gesellschaft zum Studium des Schmerzes (Member of the Board of Directors from 1997 to 2002); Deutsche Gesellschaft für Palliativmedizin (Vice-President from 2012 to 2014, President since 2014); International Associate Faculty des Institute of Palliative Medicine am San Diego Hospice (Fellow from 2010 to 2013); Expert Advisory Committee of the Federal Institute for Drugs and Medicinal Devices (Member since 2004); Drug Commission of the German Medical Board (Member since 2004); Expert Advisory Committee of the All Ireland Institute of Hospice and Palliative Care (AIHPC, member since 2010).

Patents, honours and awards

Förderpreis Palliativmedizin der Deutschen Gesellschaft für Palliativmedizin für das Jahr 2000 (Sabatowski, R., Radbruch, L., Nauck, F., Loick, G., Meuser, T., Lehmann, K.A., Entwicklung und Stand der stationären palliativmedizinischen Einrichtungen in Deutschland); 2nd Förderpreis Palliativmedizin für das Jahr 2009 (Elsner, F., Jünger, S., Pestinger, M., Krumm, N., Radbruch, L., Der Patient als Lehrer — Medizinstudierende lernen von Schwerkranken und Sterbenden); 1st Annerkennungs und Förderpreis, Ambulante Palliativversorgung für das Jahr 2009: Jünger, S., Zernikow, B., Boyè, H., Bredow, H., Caracciolo, P., Droste zu

Vischering, C., Garske, D., Grumbach-Wendt, M., Gurk, M., Hasan, C., Bode, U., Burger, A., Fleischhack, G., Kern, M., Klaschik, E., Magga, S., Maul, M., Müller, M., Reichling, S., Reichenber, C., Hahnen, M., Radbruch, L., “Ambulante pädiatrische Palliativversorgungszentren (APPZ) in NRW — der lange Weg zu einer flächendeckenden ambulanten Palliativversorgung von Kindern, Jugendlichen und jungen Erwachsenen”; TOM Medien-Sonderpreis der Deutschen Kinderhospizstiftung für das Jahr 2014 (Leidfaden Heft “Kinder und Jugendliche — ein Trauerspiel”, Heft 2 2012).

Other

Editor-in-chief of the journal *Der Schmerz* since 2004; Editor-in-chief of the journal *Leidfaden* since 2011; Editorial board of the journals *British Medical Journal*, *Palliative and Supportive Care*, *European Journal of Palliative Care*, *Palliative Medicine*, *Journal of Palliative Care*, *Zeitschrift für Palliativmedizin*; Coordinator of the ATOME consortium (Access to opioid medications in Europe), funded by the Seventh Framework programme of the European Commission since 2009.

5. Emran Razaghi (Islamic Republic of Iran)

Education

Yale World Fellow for 2004, Certificate of Fellowship, Yale World Fellows Program, Yale University, New Haven (2004-2005); Masters Degree in Public Health (M.P.H.), Faculty of Public Health, Tehran University of Medical Sciences, Tehran (2000-2002); Certificate of Training in Therapeutic Community, Colombo Plan Bureau in collaboration with DayTop International, Colombo and Singapore (1993-1995); Specialty Board of Psychiatry, Ruzbeh Psychiatric Hospital, Department of Psychiatry, Tehran University of Medical Sciences, Tehran (1987-1991); M.D., Faculty of Medicine, Tehran University of Medical Sciences, Tehran (1979-1987).

Present post

Associate Professor of Psychiatry, Department of Psychiatry, Tehran University of Medical Sciences, Tehran (since 1991).

Previous posts

Chair, Department of Psychiatry, Tehran University of Medical Sciences (2007-2014); Founder and Director, Iranian National Centre for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran (2003-2011); Director, Bureau for Psychosocial Health and the Health of Youth, Department of Health, Ministry of Health and Medical Education, Tehran (2005-2007 and 2001-2004); Deputy for Prevention and Cultural Affairs, State Welfare Organization, Tehran (1995-2001); WHO consultant to Afghanistan on “Evaluation of Afghanistan OST Pilot Project” (2011); WHO-EURO consultant to Turkmenistan on IDU/HIV harm reduction (2010); Speaker member, International Drug Policy Consortium (2010); Director, Women’s Ward I, Ruzbeh Psychiatric Hospital, Tehran (1996-2009); Associate Editor, *International Journal of Mental Health and Addiction* (2008); WHO-EMRO consultant to Sultanate of Oman on IDU/HIV harm reduction (2008);

Secretary, Legal Medicine Psychiatric Commissions, Iranian Legal Medicine Organization (2003-2005).

Memberships

Iranian Medical Association; Iranian Psychiatric Association; Iranian Scientific Association on Addictions; International Harm Reduction Association; Member, WHO Expert Committee on Drug Dependence (since 2014); Member, Executive Board, International Harm Reduction Association (2008-2013); Member, Regional Advisory Panel on Drug Abuse, WHO Regional Office for the Eastern Mediterranean (EMRO), World Health Organization (2002-2010); Member, Iranian National Committee on AIDS (2002-2010); Member, Iranian National Committee on Mental Health (1996-2011); Chair, Iranian National Committee on Drug-Related Harm Reduction (2002-2007); Chair, The Directing Board of the Scientific Association on Addictions (2001-2005); Member, The National Committee for Research on Mental Health (1999-2000); Vice-Member, The Directing Board of the Iranian Psychiatric Association (1996-2000); Member, The Scientific Board of the Iranian WHO Collaborating Centre for Mental Health (1997-1999).

Publications

Razaghi, E.M., Tabatabaee, M., Pourramzani, A., Shirali Mohammadpour, R., Mousazade Moghaddam, A., Yahyavi, S.T., "Developing an inpatient group psychotherapy programme: challenges and lessons learned", *Iranian Journal of Psychiatry and Behavioural Sciences* 9(3):e835 (2015) doi:10.17795/ijpbs-835; Bahai, T., Shojaizadeh, D., Rahimi, F.A., Ghazitabatabae, M., Moeeni, M., Rajati, F., Razaghi, E., "Effectiveness of relapse prevention cognitive-behavioural model in opioid-dependent patients participating in the methadone maintenance treatment in Iran", *Iranian Journal of Public Health* 42(8), (2013), pp. 896-902; Rahimi, M. A., Khastoo, G., Razaghi, E., Saberi, Z. M.B., Noroozi, A.R., Jarsiah, R., "Compulsory methadone maintenance treatment of severe cases of drug addiction in a residential setting in Tehran, Iran: outcome evaluation in two- and six-month follow-up", *Payesh* 10(4) (2011), pp. 503-51; Pashaei, T., Moeeni, M., Roshanaei, M. B., Heydari, H., Turner, N. E., Razaghi, E.M., "Predictors of treatment retention in a major methadone maintenance treatment programme in Iran: a survival analysis", *Journal of Research in Health Sciences*, 14(4) (2014); Asadi-Lari, M., Vaez-Mahdavi, M.R., Faghihzadeh, S., Cherghian, B., Esteghamati, A., Farshad, A.A., Golmakani, M., Haeri-Mehrizi, A.A., Hesari, H., Kalantari, N., Kamali, M., Kordi, R., Malek-Afzali, H., Montazeri, A., Moradi-Lakeh, M., Motevallian, A., Noorbala, A.A., Raghfar, H., Razzaghi, E., "Response-oriented measuring inequalities in Tehran: second round of Urban Health Equity Assessment and Response Tool (Urban HEART-2), concepts and framework", *Medical Journal of the Islamic Republic of Iran*, 27(4) (2013), pp. 236-248; Razzaghi, E. M., and Rahimi M., A., "Rapid Assessment and Response on Injection Drug Use in Tehran" (WHO multi-centre research, 2003); "Assessment of the pattern of death in Roozbeh Psychiatric Hospital in the period of 1997-2001" (Thesis title for Doctor of Medicine (M.D.) degree: Mehrabian, A., Tehran University of Medical Sciences, 2001); Hefazi, M., Sahimi-Izadian, E., Rahimi-Movaghar, A., Amin-Esmaceli, M., Razaghi, E.M., Yousefi-Nooraie, R., "The prevalence of smoking among Iranian middle school students, a systematic review", *Iranian Journal of Psychiatry* 2(4) (2007), pp. 157-164; Razzaghi, E., Nassirimanesh, B., Afshar, P., Ohiri, K., Claeson,

M., Power, R., "HIV/AIDS harm reduction in Iran", *The Lancet*, 3684 (2006), pp. 34-435;; Razzaghi, E. M., Rahimi, M., A., Green, T. C., Khoshnood, K., "Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran", *Harm Reduction Journal*, 3:12 (2006); Zamani, S., Vazirian, M., Nassirimanesh, B., Razzaghi, E., Ono-Kihara, M., Mortazavi R., Sh., Gouya, M., Kihara, M., "Needle and syringe sharing practices among injecting drug users in Tehran: a comparison of two neighbourhoods — one with and one without a needle and syringe programme", *AIDS and Behaviour*, DOI 10.1007/s10461-008-9404-2; Yasamy, M.T., Shahmohammadi, D., Bagheri Y., A., Layeghi, H., Bolhari, J., Razzaghi, E., Bina, M., Mohit, A., "Mental health in the Islamic Republic of Iran: achievements and areas of need", *Eastern Mediterranean Health Journal*, vol. 7, issue 3 (May 2001), pp. 381-391; Ofori-Adjei, D., Casswell, S., Drummond, C., Hao, W., Medina-Mora, M.E., Ranganathan, S., Razaghi, E., Room, R., Rossow, I., Samarasinghe, D.S., Weisner, C., Deluca, M., Chatterjee, A., Agossou, T., Anderson, P., Babor, T., Fleischmann, A., Souza Formigoni, M.L.O., Higuchi, S., Monteiro, M., Obot, I., Poznyak, V., Rehm, J., Rekve, D., Saraceno, B., Streel, E., Yasamy, T., "WHO Expert Committee on problems related to alcohol consumption", WHO Technical Report Series, issue 944 (2007), pp. 1-57; Rahimi M., A., Razzaghi, E. M., "A qualitative study on opioid overdose in injection drug users in Tehran", *Tehran University of Medical Sciences Journal of Faculty of Medicine*, 64, pp. 43-53 (2006); Zamani, S., Kihara, M., Gouya, M. M., Vazirian, M., Ono-Kihara, M., Razzaghi, E. M., Ichikawa, S., "Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centres in Tehran, Iran", *AIDS*, 19, pp. 709-716, (2005); Mohammadi M. R., Davidian, H., Noorbala, A. A., Malekafzali, H., Naghavi, H. R., Pouretmad, H. R., Yazdi, S. A. B., Rahgozar, M., Alaghebandrad, J., Amini, H., Razzaghi, E.M., Mesgarpour, B., Soori, H., Mohammadi, M., "An epidemiological survey of psychiatric disorders in Iran", *Clinical Practice and Epidemiology in Mental Health*, 1:16, (2005); Razzaghi, E. M., Rahimi M.A., *Injection Drug Use in Tehran*, Tehran University of Medical Sciences Publications, (2005).